Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$907.0K+346.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eyal Shamir
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 68
- Beta
- 0.43
- Country
- IL
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -12.20
Financials
Revenue
$907.0K+346.6%Net Income
$-4.50MEBITDA
$-4.35MFree Cash Flow
$-3.89MEPS (diluted)
$-1.46Shares Outstanding (diluted)
3.09M+1644.1%Operating Expenses
$4.68MCash & Debt
$12.03MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.38M | $-15.06M | $-7.10 |
| 2024 | $3.29M | $-15.32M | $-9.00 |
| 2023 | $3.23M | $-14.65M | $-9.60 |
| 2022 | $3.08M | $-16.98M | $-13.69 |
| 2021 | $4.14M | $-9.89M | $-10.20 |
| 2020 | $3.87M | $-3.73M | $-8.40 |
| 2019 | $1.66M | $-4.76M | $-10.50 |
| 2018 | $1.07M | $-3.53M | $-9.00 |
| 2017 | $689.4K | $-2.88M | $-13.80 |
| 2016 | $625.5K | $-3.27M | $-18.60 |
| 2015 | $762.9K | $-3.75M | $-24.60 |
| 2014 | $1.07M | $-4.71M | $-110.70 |
| 2013 | $354.6K | $-4.57M | $-231.00 |
Valuation
ICCMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
153+154.17%Social Signal Score
Mentions (14)
- Newsfool.com·4d ago·Positive
IceCure: 3 Key Takeaways for Long-Term Investors U.S. sales grew 83% during the first nine months. Total nine-month revenue rose 26% to $2.6 million.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
IceCure Medical Ltd (ICCM) Q3 2026 Earnings Call Transcript IceCure Medical Ltd (ICCM) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·4d ago·Negative
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.83.
View source ↗ - Newsprnewswire.com·4d ago·Neutral
…r-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States CAESAREA, Israel, Nov. 18, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported its financial and operating results as of and for the nine months ended September 30, 2026.
View source ↗ - Newsprnewswire.com·11d ago·Neutral
…dical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 CAESAREA, Israel, Nov. 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2026 b…
View source ↗ - Newsprnewswire.com·26d ago·Neutral
…Cryoablation First patient enrolled and treated at West Cancer Center in Tennessee, USA CAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has successfully completed the treatment of the first patient in its post-marketing study (the "ChoICE Study") evaluating ProSens…
View source ↗ - Newsprnewswire.com·33d ago·Neutral
…ts in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites CAESAREA, Israel, Oct. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study (the "ChoICE Study") evaluating ProSen…
View source ↗ - Newsprnewswire.com·40d ago·Neutral
…breast cancer cryoablation and highlighted strong physician engagement across Europe CAESAREA, Israel, October 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, announced today that ProSense® breast cancer cryoablation was featured in multiple scientific presentations, research posters and physician workshops …
View source ↗ - Newszacks.com·72d ago·Positive
IceCure Secures China NMPA Approval for ProSense Cryoablation System ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
View source ↗ - Newsprnewswire.com·90d ago·Negative
…ieving the highest complete ablation rate among evaluated thermal ablation technologies CAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agreement") with Scovas Medical ("Scovas") for the distribution of …
View source ↗ - Newsprnewswire.com·94d ago·Neutral
…Institutional Review Board of West Cancer Center & Research Institute in Germantown, TN CAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approva…
View source ↗ - Newsprnewswire.com·101d ago·Neutral
…cond publication extends cryoablation's clinical role to axillary lymph node metastases CAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation in breast can…
View source ↗ - Newsseekingalpha.com·102d ago·Positive
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·102d ago·Neutral
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash position CAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure M
View source ↗
Earnings
Typical surprise -6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-1.54 vs $-1.52miss
- Tue, May 12$-1.80 vs $-0.90miss
- Tue, Mar 17$-1.80 vs $-1.20miss
- Wed, Nov 19$-1.80 vs $-1.50miss
- Wed, Aug 13$-1.80 vs $-1.80beat
- Wed, May 28$-1.80 vs $-2.40beat
Estimates and results for ICCM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ICCM officers and directors.
No open-market trades in the recent filings. All 79 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ICCM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
